 | | | | Related Healthscout Videos | |
|
(Ivanhoe Newswire) -- A drug for Alzheimer's disease does not appear to slow cognitive decline, according to a new study.
Although there were promising results in a phase two trial, patients with mild Alzheimer's who received the drug tarenflurbil as part of a phase three trial did not have better outcomes on measures of cognitive decline or loss of activities of daily living compared to patients who received placebo.
Text Continues Below
The study included a randomized group of 1,684 patients who randomly were taking tarenflurbil, 800mg, or placebo each day. The patients taking tarenflurbil did not have any better results than the placebo. The drug also did not improve daily living after 18 months, according to researchers. There were also no significant differences on secondary outcomes, which included quality of life and caregiver burden.
Regarding adverse events, more participants taking tarenflurbil than those taking placebo experienced dizziness, upper respiratory tract infections and anemia.
SOURCE: JAMA, December 16, 2009
If this story or any other Ivanhoe story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Melissa Medalie at mmedalie@ivanhoe.com
This article was reported by Ivanhoe.com, who offers Medical Alerts by e-mail every day of the week. To subscribe, go to: http://www.ivanhoe.com/newsalert/.
|
.gif)
